Novo Nordisk (NVO) rallies after Ozempic trial success for kidney problems. The trial included 3,500+ people with Type 2 Diabetes with two-thirds of patients at high risk of chronic kidney disease progress. NVO stopped the Ozempic trial early after positive results for kidney issues. Caroline Woods discusses this news. Tune in to find out more about the stock market today.
Morning Trade Live
11 Oct 2023
SHARE
Morning Trade Live
07 Mar 2024
Market On Close
06 Mar 2024
Market On Close
28 Mar 2024
The Watch List
05 Mar 2024
The Watch List
02 Feb 2024
The Watch List
06 Mar 2024